longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AstraZeneca CEO praises China's pharmaceutical innovation potential, stating: Europe is being surpassed

Wallstreetcn
Mar 26, 2025 at 03:02 PM

Astrazeneca CEO Pascal Soriot warned that Europe is rapidly losing its advantage over China in pharmaceutical innovation. "Today, the two major innovators in our industry are the United States and China," Soriot said during the Boao Forum for Asia held in Hainan. "I believe that in the next five to ten years, China will become the real driving force of innovation in our industry."
Soriot has long been optimistic about China's innovation potential, but the timing of his remarks is noteworthy, as U.S.-China relations are increasingly tense, and companies are trying to align with the Trump administration. Soriot praised the Chinese government for its support of the company's investment in new research centers. He stated, "China is absolutely open to us."

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings

  • Feb 10, 2026 at 01:42 PMGlobal news you need to know before the U.S. stock market opens on Tuesday
  • Feb 10, 2026 at 08:30 AMAfter investing $18.5 billion to partner with Stone Group, AstraZeneca's earnings per share are expected to increase by …
  • Nov 11, 2025 at 01:51 PMConsolidating its position as the "largest heavyweight stock" in the UK market, pharmaceutical giant Astrazeneca's stock…
  • Jul 29, 2025 at 07:44 AMStrong sales of anti-cancer drugs, AstraZeneca's Q2 revenue increased by 12% year-on-year, exceeding expectations | Fina…
AstraZeneca

AstraZeneca

AZN.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI